QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$85.42
+0.88 (+1.04 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$83.75
Now: $85.42
$85.73
50-Day Range
$80.74
MA: $85.93
$97.70
52-Week Range
$62.48
Now: $85.42
$110.36
Volume841,178 shs
Average Volume1.55 million shs
Market Capitalization$18.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Incyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Employees1,456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.63 per share
Book Value$10.92 per share

Profitability

Net Income$446.91 million

Miscellaneous

Market Cap$18.71 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$85.42
+0.88 (+1.04 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INCY shares have increased by 18.8% and is now trading at $85.42.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Incyte?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.46 by $0.23. The biopharmaceutical company earned $620.64 million during the quarter, compared to analyst estimates of $622.48 million. Incyte had a negative return on equity of 13.66% and a negative net margin of 13.62%. The business's revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 earnings per share.
View Incyte's earnings history
.

What price target have analysts set for INCY?

23 brokers have issued 1-year target prices for Incyte's shares. Their forecasts range from $86.00 to $124.00. On average, they expect Incyte's stock price to reach $102.95 in the next year. This suggests a possible upside of 20.5% from the stock's current price.
View analysts' price targets for Incyte
.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 60, Pay $2.47M)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 49, Pay $1.2M)
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 57, Pay $847.81k)
  • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 62, Pay $803.14k)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 53, Pay $937.73k)
  • Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 56)
  • Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 49)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 54)
  • Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 69)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.80%), State Street Corp (3.99%), UBS Asset Management Americas Inc. (1.05%), California Public Employees Retirement System (0.70%), The Manufacturers Life Insurance Company (0.62%) and First Trust Advisors LP (0.51%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, UBS Asset Management Americas Inc., AQR Capital Management LLC, Victory Capital Management Inc., Los Angeles Capital Management & Equity Research Inc., NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, and WINTON GROUP Ltd. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte
.

Which institutional investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Jupiter Asset Management Ltd., Cambiar Investors LLC, Point72 Asset Management L.P., ARK Investment Management LLC, State Street Corp, TD Asset Management Inc., The Manufacturers Life Insurance Company, and Morgan Stanley.
View insider buying and selling activity for Incyte
.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $85.42.

How big of a company is Incyte?

Incyte has a market capitalization of $18.71 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.